Macrocephaly

PTEN Research Foundation Further Strengthens its Scientific Advisory Board with the Appointment of Two New Senior Leaders from the Pharmaceutical Industry

Retrieved on: 
星期三, 五月 15, 2024
Other Health, Research, General Health, Pharmaceutical, Philanthropy, Oncology, Genetics, Foundation, Science, Biotechnology, Other Science, Health, Blood, Macrocephaly, Hamartoma, Risk, Skin, Drug development, Embryo, Tissue, Mene, Gravity anomaly, FRS, Spectrum, SAB, PTEN, Physician, Breast, Endometrium, Multimedia

PTEN Research Foundation, a charity which funds and facilitates research with the aim of developing new and better treatments for the rare disease PTEN Hamartoma Tumour Syndrome (PHTS), today announced that it has further strengthened its scientific oversight of activities with two new senior leaders, Dr Donald Ogilvie and Prof Sir Mene Pangalos, joining the Foundation’s Scientific Advisory Board (SAB).

Key Points: 
  • PTEN Research Foundation, a charity which funds and facilitates research with the aim of developing new and better treatments for the rare disease PTEN Hamartoma Tumour Syndrome (PHTS), today announced that it has further strengthened its scientific oversight of activities with two new senior leaders, Dr Donald Ogilvie and Prof Sir Mene Pangalos, joining the Foundation’s Scientific Advisory Board (SAB).
  • This press release features multimedia.
  • View the full release here: https://www.businesswire.com/news/home/20240515275533/en/
    Prof Sir Menelas (Mene) Pangalos DSc PhD FRSB FMedSci HonFBPhS FRS (Photo: Business Wire)
    “We are honoured that two such senior leaders with a wealth of drug development experience have agreed to join the Foundation’s Scientific Advisory Board,” said Thomas Pepper, Chief Executive of PTEN Research Foundation.
  • In addition, people with PHTS have a significantly increased risk of developing cancer of the breast, thyroid and endometrium (lining of the womb).

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioVie Inc. of Class Action Lawsuit and Upcoming Deadlines – BIVI

Retrieved on: 
星期六, 三月 23, 2024
GCP, Macrocephaly, Prior, Shareholder, Form, Risk, District court, COVID-19, Patient, Purchasing, Ext, Acquisition, LLP, Good clinical practice, Scientific misconduct, Complaint, Insulin resistance, Clinical trial, Lung compliance, Pomerantz, Action Replay, Court, Person

NEW YORK, March 23, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against BioVie Inc. (“BioVie” or the “Company”) (NASDAQ: BIVI) and certain officers.

Key Points: 
  • NEW YORK, March 23, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against BioVie Inc. (“BioVie” or the “Company”) (NASDAQ: BIVI) and certain officers.
  • To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

BIVI INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that BioVie Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on: 
星期二, 三月 19, 2024
GCP, Macrocephaly, Risk, COVID-19, Good clinical practice, Complaint, Clinical trial, Court, Person

Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/BIVI .

Key Points: 
  • Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/BIVI .
  • or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660.
  • If you suffered a loss in BioVie you have until March 19, 2024, to request that the Court appoint you as lead plaintiff.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

BIVI 4-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages BioVie (BIVI) Investors with Substantial Losses to Contact Firm Before Mar. 19th Deadline in Securities Class Action

Retrieved on: 
星期一, 三月 18, 2024
GCP, Macrocephaly, Risk, COVID-19, Patient, News, Person, Good clinical practice, Scientific misconduct, Science, OSI, Lung compliance, Hagens Berman, Pharmaceutical industry

]” This news drove the price of BioVie shares down $1.25, or almost 30% lower, on Nov. 9, 2023.

Key Points: 
  • ]” This news drove the price of BioVie shares down $1.25, or almost 30% lower, on Nov. 9, 2023.
  • On an event call, BioVie’s management suggested that the company became aware of Phase 3 deviations beginning as early as July 2023.
  • This news drove the price of BioVie shares crashing $3.03, or over 60% lower, on Nov. 29, 2023.
  • “We’re focused on investors’ losses and are investigating whether BioVie may have intentionally concealed GCP and protocol violations,” said Reed Kathrein, the Hagens Berman partner leading the investigation.

DEADLINE ALERT for MBLY, FTFT, BIVI, and BTI: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

Retrieved on: 
星期一, 三月 18, 2024
GCP, Macrocephaly, Mobileye, Law, Fintech, Risk, COVID-19, Defendant, Security (finance), Good clinical practice, BTI, Suite, Complaint, Investment, Clinical trial, EyeQ, Future, American Tobacco Company, Lung compliance, Hand

LOS ANGELES, March 18, 2024 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.

Key Points: 
  • LOS ANGELES, March 18, 2024 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.
  • Investors suffering losses on their investments are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights in these class actions at 310-914-5007 or by email to [email protected] .
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
  • The Law Offices of Frank R. Cruz, Los Angeles

BIVI DEADLINE ALERT: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages BioVie Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important March 19 Deadline in Securities Class Action – BIVI

Retrieved on: 
星期五, 三月 15, 2024
Titan, GCP, Macrocephaly, Organization, Risk, COVID-19, Research, Class, Good clinical practice, Clinical trial, Lung compliance, Advertising, Court

WHAT TO DO NEXT: To join the BioVie class action, go to https://rosenlegal.com/submit-form/?case_id=21342 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the BioVie class action, go to https://rosenlegal.com/submit-form/?case_id=21342 or call Phillip Kim, Esq.
  • If you wish to serve as lead plaintiff, you must move the Court no later than March 19, 2024.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

BIVI 4-DAY DEADLINE ALERT: Hagens Berman Encourages BioVie (BIVI) Investors with Substantial Losses to Contact Firm Before Mar. 19th Deadline

Retrieved on: 
星期五, 三月 15, 2024
GCP, Macrocephaly, Risk, COVID-19, Patient, SAN, News, Person, Good clinical practice, Scientific misconduct, Science, OSI, Lung compliance, Hagens Berman, Pharmaceutical industry

SAN FRANCISCO, March 15, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges BioVie Inc. (NASDAQ: BIVI) investors who suffered substantial losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, March 15, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges BioVie Inc. (NASDAQ: BIVI) investors who suffered substantial losses to submit your losses now .
  • ]” This news drove the price of BioVie shares down $1.25, or almost 30% lower, on Nov. 9, 2023.
  • This news drove the price of BioVie shares crashing $3.03, or over 60% lower, on Nov. 29, 2023.
  • “We’re focused on investors’ losses and are investigating whether BioVie may have intentionally concealed GCP and protocol violations,” said Reed Kathrein, the Hagens Berman partner leading the investigation.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioVie Inc. (BIVI)

Retrieved on: 
星期五, 三月 15, 2024
GCP, Macrocephaly, Risk, COVID-19, Patient, GPM, Defendant, News, Good clinical practice, Scientific misconduct, Suite, Clinical trial, Lung compliance, Court

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • ]”
    On this news, BioVie’s stock price fell $1.25, or 29.3%, to close at $3.01 per share on November 9, 2023, thereby injuring investors.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • Glancy Prongay & Murray LLP, Los Angeles

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioVie Inc. of Class Action Lawsuit and Upcoming Deadlines – BIVI

Retrieved on: 
星期五, 三月 15, 2024
GCP, Macrocephaly, Shareholder, Form, Risk, District court, COVID-19, Patient, Purchasing, Ext, Acquisition, LLP, Good clinical practice, Scientific misconduct, Complaint, Insulin resistance, Clinical trial, Lung compliance, Pomerantz, Action Replay, Court, Person

NEW YORK, March 15, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against BioVie Inc. (“BioVie” or the “Company”) (NASDAQ: BIVI) and certain officers.

Key Points: 
  • NEW YORK, March 15, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against BioVie Inc. (“BioVie” or the “Company”) (NASDAQ: BIVI) and certain officers.
  • To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

BioVie (BIVI) Faces Securities Fraud Class Action After Uncovering Potential Scientific Misconduct In Failed Phase 3 Clinical Trial – Hagens Berman

Retrieved on: 
星期二, 三月 12, 2024
GCP, Macrocephaly, Risk, COVID-19, Patient, SAN, News, Person, Good clinical practice, Scientific misconduct, Science, OSI, Lung compliance, Hagens Berman, Pharmaceutical industry

SAN FRANCISCO, March 12, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges BioVie Inc. (NASDAQ: BIVI) investors who suffered substantial losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, March 12, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges BioVie Inc. (NASDAQ: BIVI) investors who suffered substantial losses to submit your losses now .
  • The litigation focuses on the propriety of BioVie’s disclosures concerning its adherence to Good Clinical Practice (“GCP”) and protocols related to its Phase 3 clinical trial of NE3107, a potential Alzheimer’s disease drug.
  • ]” This news drove the price of BioVie shares down $1.25, or almost 30% lower, on Nov. 9, 2023.
  • “We’re focused on investors’ losses and are investigating whether BioVie may have intentionally concealed GCP and protocol violations,” said Reed Kathrein, the Hagens Berman partner leading the investigation.